
## Doctor, may I request MRI for my "lung mass"





## Case 1

A 56-year-old gentleman was referred to Wong Tai Sing Hospital for evaluation of lung shadow on chest X ray in June 2017. The patient was a property maintenance staff with past medical history of hypertension, hyperlipidemia, impaired fasting glucose and varicose vein followed up at general outpatient clinic (GOPC). He was a non-smoker. He complained of cough with whitish sputum during and consulted GOPC in April 2017. He also had 1 episode of small amount of blood stained sputum, otherwise there were no other respiratory

symptoms or constitutional symptoms. On physical examination he did not have any cervical lymphadenopathy or finger clubbing. The examination of chest or other system was unremarkable. CXR at GOPC (Figure 1) showed a 2cm right upper zone subpleural lesion with well-defined medial border but indistinct lateral border, which slowly increased in size compared with previous CXR. Therefore, the patient was referred for further investigation.



Figure 1. Right upper zone subpleural lesion with well-defined medial border but indistinct lateral border

Computer tomography (CT) with contrast was arranged (Figure 2), which showed a pleural-based lesion over the right posterior-lateral hemithorax at the level of posterior-segment of the right upper lobe. It measured 3cm x 1cm in size, and was well-defined with minimal contrast enhancement. It did not showed any invasion into lung parenchyma or erosion of the ribs. There were no mediastinal lymphadenopathies or pleural effusion.



Figure 2. Pleural-based lesion over the right posterior-lateral hemithorax at the level of posterior-segment of the right upper lobe

The management approach to patients with suspected pleural lesion will be outlined. Patients may remain asymptomatic especially with small pleural lesion. Symptoms such as chest or shortness of breath should be checked. Recurrent hypoglycemia may be present in patients with solitary fibrous tumor of the pleura due to secretion of insulin-like growth factor.<sup>1</sup> Environmental exposure and occupation is important for diseases such as asbestosis. For past medical history, particular attention should be paid to prior malignancy as pleural metastasis is the most common pleural tumor. Upon physical examination, finger clubbing and

28

cervical lymphadenopathy should be checked. Pleural effusion may be detected, but chest exam may be normal. For imaging approach to suspected pleural lesion, the first step is to differentiate between pulmonary and extra-pulmonary lesion (Table 1).<sup>2</sup>

Pulmonary	Extra-pulmonary
Acute angle with chest wall	Obtuse angle with chest wall
Non-tapered ill-defined border	Tapered well-defined border Incomplete border sign
Centered in the lung	Centered along chest wall
Engulf pulmonary vasculature on axial imaging	Displaces vasculature on axial imaging

Table 1. Differentiation between pulmonary and extra-pulmonary lesion (Modified from reference 2)

Incomplete border sign was demonstrated in our case. This can be attributed to the fact that medial margin of the pleural lesion was tangential to the x-ray beam and had good inherent contrast with the adjacent lung. On the other hand, the outer margin was en face or partially en face with the x-ray beam and merged with the pleura thus this part of the border was obscured.<sup>3</sup>

After localizing the lesion to extrapulmonary area, the next step is to differentiate whether the lesion is a pleural or an extrapleural one (Table 2).

Pleural	Extrapleural
Outward displacement of extrapleural fat	Inward displacement of extrapleural fat
Rib erosion relatively uncommon	Rib erosion relatively more common

Table 2. Differentiation between pleural and extra-pleural lesion (Modified from reference 2)

CT is the most commonly utilized imaging modality for evaluation of pleural lesion. It can

confirm the location and determine extent of the pleural lesion. It is superior than MRI for

detecting calcification and bony destruction and useful for guidance for FNA or biopsy.<sup>4</sup> On CT, features suggestive of pleural malignancy include circumferential pleural thickening, nodular pleural thickening, mediastinal pleural involvement and parietal pleural thickening more than 1cm.<sup>5</sup>

Magnetic resonant imaging (MRI), while less commonly employed, is another handy tool for evaluation of pleural disease. It has superior soft tissue contrast- and spatial-resolution compared with CT. It is good at demonstrating infiltration of the chest wall, diaphragm or other adjacent tissues by malignant disease which is important in determining resectability.<sup>6</sup> Morphological features of pleural malignancy are similar to that of CT (mediastinal pleural involvement, circumferential pleural thickening, nodularity, contour irregularity, and infiltration of the chest wall or diaphragm). A retrospective study published in CHEST in 2000 found that if one or more morphological features were present, it would give a sensitivity 96% and specificity of 80% for pleural malignancies.<sup>7</sup> One important point raised by this study was that tuberculous empyema, when extensive, may involve the mediastinal pleura. Apart from morphological features, signal intensity on MRI also aids the diagnosis. High signal intensity in relation to intercostal muscles on T2-weighted and/or contrast-enhanced T1-weighted images was found to be suggestive for a malignant pleural

disease. Combining morphologic features with the signal intensity features, MRI had sensitivity up to 100% and a specificity of 93% in the detection of pleural malignancies.<sup>7</sup>

Positive emission tomography (PET)/ PET-CT was also evaluated for its efficacy for pleural diseases. Meta-analysis in 2014 showed PET/PET-CT had a sensitivity 95% and specificity 82% for pleural malignancy.<sup>8</sup> False positive results may be present in infection or inflammatory lesions e.g. after talc pleurodesis. False negative results can be present in small malignant lesions or low-grade malignancies with low proliferative activity e.g. epithelioid subtypes of mesothelioma. The role of dual time-point 18F-FDG-PETor PET/CT in differentiating between malignant and benign pleural lesions is still controversial.<sup>9</sup>

For solitary pleural lesion, the differential diagnoses should include metastatic and primary pleural tumors, as well as benign pathologies that mimic pleural tumors. Pleural metastasis is the most frequently encountered pleural tumor. Primary pleural tumors are uncommon and are divided into mesothelial tumors (e.g. malignant mesothelioma), lymphoproliferative disorders (e.g. primary effusion lymphoma) and mesenchymal tumors (e.g. solitary fibrous tumor) according to the WHO classification.<sup>10</sup> Benign pathologies that can mimic pleural tumors include loculated fluid or pleural pseudotumor, pleural plaque, thoracic splenosis and thoracic endometriosis

Our patient had CT guided pleural biopsy which showed a cores of tumor tissue. It was composed of short spindle cells in a collagenous stroma. Mitotic figures were not seen, which suggested benign pathology. Immunostaining result showed some of the spindle cells are S100 positive and some are CD 34 positive, which was suggestive of Schwannian differentiation and endoneurial fibroblast differentiation.<sup>11</sup> The overall features are spindle cell neoplasm, suggestive of pleural Neurofibroma.

The final diagnosis of our patient was pleural neurofibroma. Neurofibroma is а benign peripheral nerve sheath tumor, which comprised of a mixture of Schwann cells, fibroblasts, perineurial cells, and mast cells.<sup>12</sup> The majority solitary and not associated with is neurofibromatosis type 1 (NF 1). Neurofibroma are divided into localised, diffuse and plexiform types. While localized cutaneous neurofibroma is the most common form, neurofibroma can potentially involve any nerve from the root level to the smallest branch.

Localised pleural neurofibroma is a very rare disease entity of the pleura. We have performed a literature search and only found 1 case report and 1 case series describing the disease.

Langman et al. reported a 78-year-old female who complained of shoulder pain without any respiratory symptoms.<sup>11</sup> Chest X ray showed a 2.5 cm pleural based nodule. She received VATS excision with no recurrence on 6 years of follow up. Mayo Clinic published a case series 2015 which described in 15 cases of pleuroparenchymal peripheral nerve sheath tumors, including 3 cases of neurofibroma.<sup>13</sup> Patients presented with shortness of breath, cough or incidental finding. No details regarding treatment were provided, but all patients had good outcome with no mortality reported with an average of 43 months of follow up.

On the other hand, pleural neurofibroma in NF 1 was more well reported in the literature. It is associated with risk of spontaneous hemorrhage and hemothorax, due to the angiogenic and invasive properties of the abnormal Schwann cells in plexiform neurofibromas.<sup>14</sup> Intercostal arteries and subclavian arteries are commonly involved.<sup>15</sup> Aggressive surgical treatment is required in hemodynamically unstable patients due to high mortality (up to 30% mortality).

Pleural neurofibroma in NF 1 patients is also associated with risk of malignant transformation into malignant peripheral nerve sheath tumor (MPNST), especially with plexiform neurofibroma. There is an estimated 5% lifetime risk of malignant transformation, which can present as chest pain or rapid growth of a nodule within an existing plexiform neurofibroma.<sup>16</sup> Potential pitfalls exist when obtaining tissue diagnosis for MPNST. There is potential sampling error because benign areas could be contiguous with the malignant ones.<sup>17</sup> Pleural MPNST could be misdiagnosed as mesothelioma or non-small cell lung cancer as well.<sup>18</sup>

In view of the potential complications of hemorrhage and malignant transformation, features of NF 1 were explored. The patient had 5 well defined brownish spots over bilateral lower limbs, largest one measuring 6mm, otherwise there were no café-au-lait spots seen. He did not have any cutaneous neurofibroma, axillary or inguinal freckling. His neurological exam including the cranial nerves and vision were normal. There was no bone deformity. He did not have any family history of NF. He did not fulfill the National Institutional of Health diagnostic criteria for neurofibromatosis type 1.<sup>19</sup> In view of the increasing size of the pleural neurofibroma, was he referred to the cardiothoracic surgeon for excision. However, the patient defaulted follow-up. He was planned for serial imaging monitoring of the pleural neurofibroma.

1. Walker CM, Takasugi JE, Chung JH, et al. Tumorlike conditions of the pleura. *RadioGraphics*. 2012;32(4):971-985. 2. Sureka B, Thukral BB, Mittal MK, Mittal A, Sinha M. Radiological review of pleural tumors. *Indian J Radiol Imaging*. 2013;23(4):313-320.

3. Hsu CC, Henry TS, Chung JH, Little BP. The incomplete border sign. *J Thorac Imaging*. 2014;29(4):W48.

4. Bruns AS, Mastronarde JG. Imaging of pleural masses: Which to choose? *Respir Med*. 2008;102(3):328-331.

5. Leung AN, Müller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. *AJR Am J Roentgenol*. 1990;154(3):487-492.

6. Bittner RC, Felix R. Magnetic resonance (MR) imaging of the chest: State-of-the-art. *Eur Respir J.* 1998;11(6):1392-1404.

7. Hierholzer J, Luo L, Bittner RC, et al. MRI and CT in the differential diagnosis of pleural disease. *Chest.* 2000;118(3):604-609.

8. Treglia G, Sadeghi R, Annunziata S, et al. Diagnostic accuracy of 18F-FDG-PET and PET/CT in the differential diagnosis between malignant and benign pleural lesions: A systematic review and meta-analysis. *Acad Radiol.* 2014;21(1):11-20.

9. Kruse M, Sherry SJ, Paidpally V, Mercier G, Subramaniam RM. FDG PET/CT in the management of primary pleural tumors and pleural metastases. *AJR Am J Roentgenol*. 2013;201(2):215. 10. Galateau-Salle F, Churg A, Roggli V, Travis WD. The 2015 world health organization classification of tumors of the pleura: Advances since the 2004 classification. *J Thorac Oncol.* 2016;11(2):142-154.

 Langman G, Rathinam S, Papadaki L.
 Primary localised pleural neurofibroma: Expanding the spectrum of spindle cell tumours of the pleura. *J Clin Pathol.* 2010;63(2):116-118.

 Rodriguez FJ, Folpe AL, Giannini C, Perry A. Pathology of peripheral nerve sheath tumors: Diagnostic overview and update on selected diagnostic problems. *Acta Neuropathol*. 2012;123(3):295-319.

13. Boland JM, Colby TV, Folpe AL. Intrathoracic peripheral nerve sheath tumors-a clinicopathological study of 75 cases. *Hum Pathol.* 2015;46(3):419-425.

14. Miura T, Kawano Y, Chujo M, Miyawaki M,
Mori H, Kawahara K. Spontaneous hemothorax
in patients with von recklinghausen's disease. *Jpn J Thorac Cardiovasc Surg.*2005;53(12):649-652.

15. Pulivarthi S, Simmons B, Shearen J, Gurram MK. Spontaneous hemothorax associated with neurofibromatosis type I: A review of the literature. *J Neurosci Rural Pract*. 2014;5(3):269-271. 16. Karadurmus N, Basaran Y, Buyukturan G, Safali M. Neurofibromatosis type 1 complicated with malignant transformation and diffuse pulmonary disease. *Journal of Oncological Sciences*. 2016;2(2):84-86.

17. Kim JG, Sung WJ, Kim DH, Kim YH, Sohn SK, Lee KB. Malignant peripheral nerve sheath tumor in neurofibromatosis type I: Unusual presentation of intraabdominal or intrathoracic mass. *Korean J Intern Med.* 2005;20(1):100-104.

 Misiak P, Wcislo S, Jabłoński S, Szwalbe K.
 Primary malignant peripheral nerve sheath tumor of the pleural cavity: Rapid progression.
 *Polish journal of cardio-thoracic surgery*.
 2014;11(2):213-215.

19. Ferner RE, Huson SM, Thomas N, et al. Guidelines for the diagnosis and management of individuals with neurofibromatosis 1. *Journal of medical genetics*. 2007;44(2):81-88.